

MARKSANS PHARMA LIMITED

Regd. Office: 11th Floor, Lotus Business Park, Off. New Link Road, Andheri (West), Mumbai-400053
UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH SEPTEMBER, 2013

PART 1

Sr. No.	PARTICULARS	3 MONTHS ENDED				6 MONTHS ENDED		Previous Year ended 31.03.2013 (AUDITED)
		30.9.2013 (UNAUDITED)	30.06.2013 (UNAUDITED)	30.9.2012 (UNAUDITED)	30.9.2013 (UNAUDITED)	30.9.2012 (UNAUDITED)		
1	Income							
a-	Net Sales/ Income from Operations (Net of excise duty)	16,135.40	14,103.11	10,552.64	30,238.51	20,016.86	43,842.24	
b-	Other Operating Income	2.45	272.17	365.41	274.62	437.51	439.54	
	Total Income from operations (net)	16,137.85	14,375.28	10,918.05	30,513.13	20,454.37	44,281.78	
2	Expenses							
a)	Cost of Material Consumed	5,870.39	4,313.89	3,630.40	10,184.28	6,650.86	13,592.88	
b)	Purchase of Stock - in-trade	3,399.51	3,421.11	2,364.05	6,820.62	4,767.48	10,478.15	
c)	Changes in Inventories of finished goods, work-in-progress and stock - in-trade	(45.23)	155.79	(0.32)	110.56	(2.81)	1,215.43	
d)	Employee benefits expense	1,853.41	1,518.01	1,350.29	3,371.41	2,579.60	5,591.25	
e)	Depreciation and amortisation expense	317.50	320.54	498.77	638.04	751.52	1,564.99	
f)	Other expenses	2,094.22	1,787.61	1,273.80	3,881.83	5,185.16	6,024.71	
	Total Expenses	13,459.80	11,516.95	9,116.99	25,006.74	19,931.81	38,467.41	
3	Profit/(Loss) from Operations before other income, finance costs and exceptional items (1-2)	2,648.05	2,858.33	1,801.06	5,506.39	522.56	5,814.37	
4	Other Income	-	-	-	-	-	-	
5	Profit/(Loss) from Ordinary activities before finance costs and exceptional items(3+4)	2,648.05	2,858.33	1,801.06	5,506.39	522.56	5,814.37	
6	Finance cost	399.41	859.14	341.29	1,258.54	700.72	1,459.64	
7	Profit/(Loss) from ordinary activities after finance costs but before exceptional items(5-6)	2,248.64	1,999.19	1,459.77	4,247.85	(178.16)	4,354.73	
8	Exceptional items	-	-	-	-	-	-	
9	Profit/(Loss) from Ordinary activities before Tax (7-8)	2,248.64	1,999.19	1,459.77	4,247.85	(178.16)	4,354.73	
10	Tax Expenses (Includes Deferred Tax & Tax for Earlier Year)	195.51	82.78	1,459.77	278.29	-	(527.89)	
11	Net Profit/(Loss) from Ordinary activities after tax(9-10)	2,053.13	1,916.41	1,459.77	3,969.56	(178.16)	4,882.62	
12	Less: Extraordinary item	-	-	-	-	-	-	
13	Net Profit/ (Loss) for the period (11-12)	2,053.13	1,916.41	1,459.77	3,969.56	(178.16)	4,882.62	
14	Share of Profit/(Loss) of associates	-	-	-	-	-	-	
15	Minority Interest	52.06	38.10	57.28	90.16	127.01	294.19	
16	Net Profit/(Loss) after taxes, minority interest and share of associates(13-14-15)	2,001.07	1,878.31	1,402.49	3,879.40	(305.17)	4,588.43	
17	Paid up Equity Share Capital (Face Value Re.1 each)	3,853.07	3,853.07	3,678.07	3,853.07	3,678.07	3,853.07	
18	Reserve Excluding Revaluation Reserve as per Balance Sheet of Previous Accounting year	-	-	-	-	-	-	
19	a) Earnings Per Share (before extraordinary items, Rs.)- Basic	0.53	0.50	0.40	1.03	(0.05)	3,444.80	
	Diluted	0.53	0.50	0.38	1.03	(0.05)	1.27	
	b) Earnings Per Share(after extraordinary items- Rs.)- Basic	0.52	0.49	0.38	1.01	(0.06)	1.19	
	Diluted	0.52	0.49	0.36	1.01	(0.08)	1.19	
PART 2								
A PARTICULARS OF SHAREHOLDING								
1	Public Shareholding:							
	- Number of Shares	187,815,471	187,999,472	189,824,114	187,815,471	189,824,114	188,634,244	
	- Percentage of Holding	48.75%	48.79%	51.61%	48.75%	51.61%	48.96%	
2	Promoters and Promoter group Shareholdings	197,491,733	197,307,732	177,983,090	197,491,733	177,983,090	196,672,960	
	a). Pledged/Encumbered							
	- Number of Shares	NIL	NIL	NIL	NIL	NIL	NIL	
	- Percentage of Holding (as a % of the total shareholding of Promoter and Promoter Group)	N.A	N.A	N.A	N.A	N.A	N.A	
	- Percentage of Holding (as a % of the total share capital of the Company)	N.A	N.A	N.A	N.A	N.A	N.A	
	b). Non-encumbered							
	- Number of Shares	197,491,733	197,307,732	177,983,090	197,491,733	177,983,090	196,672,960	
	- Percentage of Holding (as a % of the total shareholding of Promoter and Promoter Group)	100%	100%	100%	100%	100%	100%	
	- Percentage of Holding (as a % of the total share capital of the Company)	51.25%	51.21%	48.39%	51.25%	48.39%	51.04%	



B/ INVESTOR COMPLAINTS	3 MONTHS ENDED
Pending at the beginning of the quarter	30.9.2013
Received during the quarter	Nil
Disposed of during the quarter	2
Remaining unresolved at the end of the quarter	2

PART 3	Standard Information	3 MONTHS ENDED					Previous Year ended
		30.09.2013	30.06.2013	30.9.2012	30.9.2013	30.9.2012	
	PARTICULARS	(UNAUDITED)	(UNAUDITED)	(UNAUDITED)	(UNAUDITED)	(AUDITED)	
	Revenue	7,851.37	7,472.47	5,028.81	15,323.83	8,852.08	
	Profit Before Tax from Ordinary activities	1,872.88	1,720.79	1,439.82	3,693.47	2,960.50	
	Profit After Tax from Ordinary activities	1,779.85	1,678.83	1,439.82	3,458.47	3,958.27	
	Profit After Tax after extraordinary item	1,779.85	1,678.83	1,439.82	3,458.47	(533.01)	

- Notes:
- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 31.10.2013.
 - The Consolidated Financial Statements include Financial Statements of the subsidiaries Nova Pharmaceuticals Australia Pty Ltd and Marisans Pharma (UK) Limited.
 - The Consolidated Financial Statements are prepared in accordance with Accounting Standard 21 "Consolidated Financial Statement" issued by the Institute of Chartered Accountants of India.
 - The Company is primarily engaged in a single business segment of Manufacturing & Marketing of Pharmaceutical Formulations.
 - The Company will consider the effect of Deferred Tax Asset/(Liabilities) - AS 22 in the audited accounts at the year end.
 - Previous year's figures have been re-grouped/re-classified, wherever necessary, so as to make them comparable with the current year's figures.
 - Statement of Assets and Liabilities:

A	Particulars	As at		B
		30.09.2013	31.03.2013	
	EQUITY AND LIABILITIES	UNAUDITED	AUDITED	
1	Shareholders' funds			
(a)	Share capital	5,203.07	5,203.07	
(b)	Reserves and surplus	6,158.81	3,444.80	
(c)	Money received against share warrants			
	Sub-total-Shareholders' funds	11,361.88	8,647.87	
2	Minority Interest	609.96	699.00	
3	Non-current liabilities			
(a)	Long-term borrowings	654.64	787.68	
(b)	Deferred tax liabilities (Net)	270.51	261.64	
	Sub-total - Non-current liabilities	925.15	1,049.32	
4	Current liabilities			
(a)	Short-term borrowings	12,070.40	11,378.70	
(b)	Trade payables	6,419.26	5,606.16	
(c)	Other current liabilities	9,616.67	10,673.44	
(d)	Short-term provisions	2,797.32	1,889.96	
	Sub-total-Current liabilities	30,903.65	29,728.26	
	TOTAL-EQUITY AND LIABILITIES	43,800.84	40,124.45	
	ASSETS			
1	Non-current assets			
(a)	Fixed assets	15,222.03	15,452.63	
(b)	Goodwill on consolidation	159.00	159.00	
(c)	Non-current Investments			
(d)	Long-term loans and advances	119.25	120.21	
	Sub-total - Non-current assets	15,500.28	15,731.84	
2	Current assets			
(a)	Inventories	10,439.48	7,789.19	
(b)	Trade receivables	16,203.61	13,131.42	
(c)	Cash and cash equivalents	677.47	1,588.00	
(d)	Short-term loans and advances	980.00	1,904.00	
(e)	Other current assets- Miscellaneous expenditure			
	Sub-total-Current assets	28,300.56	24,392.61	
	TOTAL ASSETS	43,800.84	40,124.45	

₹ in Lakhs

Place: Mumbai,
Date: 31.10.2013
www.marisanspharma.com



For MARKSANS PHARMA LIMITED
MARK SALLADANA
Managing Director.